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Androgen signalling is a critical driver of male development. fetal steroid signalling can be dysregulated 
by a range of environmental insults and clinical conditions. We hypothesised that poor adult male 
health was partially attributable to aberrant androgen exposure during development. testosterone 
was directly administered to developing male ovine fetuses to model excess prenatal androgenic 
overexposure associated with conditions such as polycystic ovary syndrome (pcoS). Such in utero 
androgen excess recreated the dyslipidaemia and hormonal profile observed in sons of PCOS patients. 
1,084 of 15,134 and 408 of 2,766 quantifiable genes and proteins respectively, were altered in the liver 
during adolescence, attributable to fetal androgen excess. furthermore, prenatal androgen excess 
predisposed to adolescent development of an intrahepatic cholestasis-like condition with attendant 
hypercholesterolaemia and an emergent pro-fibrotic, pro-oxidative stress gene and protein expression 
profile evident in both liver and circulation. We conclude that prenatal androgen excess is a previously 
unrecognised determinant of lifelong male metabolic health.
Prenatal programming of health and disease is driven by maternal/fetal endocrine alterations1,2, maternal nutri-
tional status3 and maternal/fetal chemical insults4. During development, interactions between endogenous hor-
mones, underlying endocrine disease and/or environmental exposure to toxicants, such as endocrine disrupting 
compounds (EDC)5 impact upon postnatal health, and thus the incidence of chronic disease6, with attendant 
economic burdens7,8.
The linkage between adult health and altered prenatal androgen exposure is robust. Androgens, secreted by 
developing testes9 and other organs10 promote masculinisation in target tissues expressing androgen receptors. 
In addition to pathologies of insufficient androgen exposure, for example hypospadias11, excess exposure may 
also occur, for example, in offspring of hyperandrogenaemic women with polycystic ovary syndrome (PCOS) or 
congenital adrenal hyperplasia12. Human data and animal experimentation has demonstrated aetiological con-
tributions of prenatal androgen overexposure to the development of PCOS in female offspring13, linking the 
reproductive phenotype with metabolic phenotypes, including insulin resistance (IR), obesity and dyslipidae-
mia. This is underscored by morphometric markers of increased prenatal androgens in women with PCOS and 
their daughters14,15, and male range umbilical cord blood androgen concentrations in daughters of women with 
PCOS16. Indeed animal models designed to recreate PCOS-associated pathologies utilise over-exposure of female 
fetuses/pregnant dams to androgenic steroids1,17–25.
Male offspring from human PCOS pregnancies also develop hyperinsulinaemia and dyslipidaemia, predicting 
potentially increased risk of cardiovascular disease26–28. Elevated cholesterol is an early marker of metabolic dys-
function in pubertal sons of PCOS patients29. Early metabolic changes in PCOS sons are likely to be independent 
of gonadotropin and sex steroid levels although they have elevated anti-Müllerian hormone (AMH) concentra-
tions during childhood30.
We hypothesised that androgen excess during male fetal development increases the risk of developing liver 
dysfunction and dyslipidaemia. The aims of the study were, in an animal model of prenatal androgen excess: 1. 
Determine whether dyslipidaemia observed in PCOS-patient male relatives may have early-life-environment 
contributions. 2. Comprehend hepatic mechanisms behind prenatally programmed dyslipidaemia. 3. Determine 
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circulating proteins reflective of prenatally programmed liver dysfunction prior to overt disease symptom 
development.
We discovered that fetal androgen excess was linked to adolescent male hepatic dysfunction/dyslipidaemia, 
elucidated mechanisms underpinning fetal androgen-excess programming of postnatal hepatic dysfunction, and 
identified circulating markers reflective of such programming in adolescence.
Results
prenatal androgen treatment replicates human male pcoS-offspring characteristics. 
Circulating biomarkers characteristic of the sons of women with PCOS were examined in male sheep from con-
trol and prenatally androgen treated pregnancies. AMH and insulin were significantly elevated in adolescent 
prenatally androgen treated males (P < 0.05), but testosterone concentrations were comparable with control off-
spring (Fig. 1a). Plasma from prenatally androgen treated sheep therefore replicated circulating biomarkers of 
PCOS patients first degree male relatives26–30.
evidence of dyslipidaemia. Adolescent prenatally androgen treated males had increased plasma triglyc-
erides (0.90 ± 0.08 mmol/l vs 0.58 ± 0.07 mmol/l; P < 0.05) (Fig. 1a) and elevated total cholesterol concentrations 
(3.27 ± 0.25 nmol/l vs 1.7 ± 0.16 mmol/l; P < 0.0001) (ovine reference range 1.3–1.96 mmol/l31) compared with 
control offspring indicative of hypercholesterolaemia (Fig. 1b). Both LDL cholesterol (P < 0.001) and HDL cho-
lesterol (P < 0.0001) concentrations were increased in adolescent prenatally androgen treated males when com-
pared to controls (Fig. 1b).
prenatal programming of hepatic lipid metabolism. The hepatic transcriptome analysis revealed 
15,134 expressed genes for analysis after low count transcript removal, with 1,084 differentially expressed genes 
in adolescent life between control and prenatally androgen treated livers (FDR adjusted P < 0.05). Hepatic pro-
teome analysis quantified and identified 2766 proteins, with 408 differentially expressed in adolescent life between 
control and prenatally androgen treated livers (P < 0.05). Of the 449 plasma proteins quantified and identified, 
96 were differentially expressed in adolescent prenatally androgen treated males compared to control animals 
(P < 0.05). Collectively, bioinformatics analysis indicated the prenatally-programmed dysregulation of pathways 
involved in lipid metabolism, metabolism of cholesterol, sterol synthesis, cholesterol synthesis and lipid home-
ostasis, together with prediction of altered cholesterol concentrations (Table 1), manifesting in plasma as hyper-
cholesterolaemia (Fig. 1b).
prenatally programmed dysregulation of hepatic cholesterol synthesis, uptake and secretion 
pathways. Analysis of differentially expressed hepatic genes and proteins between control and prenatally 
androgen treated males revealed a consistent reduction in the cholesterol synthesis pathway (Fig. 2). When genes 
involved in the hepatic import pathways were analysed the significant differences pointed to an increased poten-
tial for cholesterol uptake (Fig. 2). Within the liver there was also increased mRNA encoding genes critical for 
esterification and assembly of lipoproteins with increased apolipoprotein expression. In addition, gene expression 
of cholesterol and phospholipid efflux potential into the bile was increased (Table 2). There is thus transcriptional 
evidence for augmented hepatic pathways involved in cholesterol efflux. However, the hypercholesterolemia in 
prenatally androgen treated males cannot be explained by increased hepatic cholesterol synthesis or reduced 
uptake into the liver.
Dysregulation of the enterohepatic circulation. While there was evidence of increased capacity for 
cholesterol and phospholipid secretion into the bile, the same was not true for the secretion of bilirubin, bile 
acids and organic substrates (Fig. 3), predicting increased risk of bilirubin and bile acids accumulation within the 
liver. Adolescent prenatally androgen treated males had significantly increased hepatic bilirubin content as com-
pared with adolescent controls (P < 0.001) (Fig. 4), with foci of accumulation reminiscent of human cholestasis 
histopathology. Prenatally androgen treated males also exhibited markedly higher circulating concentrations of 
bilirubin as compared to control pregnancy male offspring during adolescence (3.8 ± 0.44 µmol/l vs 2.27 ± 0.22 
µmol/l; P < 0.01) (Fig. 4).
Bile acids directly interact with several nuclear receptors within the liver. There were clear effects on genes 
that mediate bile acid action and homeostasis in prenatally androgen treated males (Fig. 3). While it is difficult 
to predict the net outcome of these changes it is clear that hepatic bile acid synthesis (via. CYP7A1) is likely to be 
reduced (Fig. 2). Bioinformatic analysis of the hepatic proteome predicted altered bile acid synthesis (Table 1). 
There was no difference in total circulating bile acids in prenatally androgen treated males (12.79 ± 2.36 µmol/l) as 
compared to control pregnancy offspring (9.39 ± 1.67µmol/l) (P = 0.16) (Fig. 4). Plasma ALP, known to increase 
during cholestasis, was increased in PA males (892.9 ± 83.8 U/L) as compared to control males (535.5 ± 67.8 U/L) 
during adolescence (P < 0.01) (Fig. 4). Bioinformatic analysis of the prenatally androgen treated male hepatic 
transcriptome predicted intrahepatic cholestasis and analysis of the hepatic proteome also predicted cholestasis 
(Table 1).
Reduced hepatic detoxification potential. Hepatic transcriptome analysis identified the potential for 
liver damage in prenatally androgen treated males. Liver damage, drug-induced liver disease and hepatocyte 
proliferation pathways were identified by bioinformatics analysis (Table 1). Hepatic proteome bioinformatics also 
predicted an increase of oxidative stress in livers of adolescent prenatally androgen treated males, accompanied by 
decreased hydrogen peroxide metabolism and increased synthesis of reactive oxygen species (Table 1). Moreover, 
there was a prediction of altered concentration of glutathione and increased cell death (Table 1). Bioinformatic 
analysis of the plasma proteome indicated increased biosynthesis of hydrogen peroxide, metabolism of reactive 
oxygen species and synthesis of reactive oxygen species (Table 1). There was a general reduction in the expression 
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of hepatic genes and proteins relevant to both liver detoxification potential and liver reactive oxygen species 
(ROS) detoxification as a consequence of prenatal androgen excess in males (Table 2). Overall the emergent pic-
ture is one of reduced hepatic detoxification and potential liver damage.
early liver damage. There was no difference between prenatally androgen treated males (14.86 ± 1.67 U/L) 
and control males (19.46 ± 2.52 U/L) (P = 0.13) in concentrations of plasma alanine aminotransferase (ALT), a 
marker of hepatocellular damage. This is despite the observation, mentioned above, that ALP was significantly 
increased in prenatally androgen treated animals. However, the plasma transcriptome predicted fibrosis, liver 
lesion, hepatic injury and liver cirrhosis (Table 1). We interrogated expression of differentially expressed genes 
and proteins relevant to liver fibrosis as a potential consequence of liver damage, cell death and proliferation 
(Table 3). The resulting data suggest that these males have an increased potential for hepatic fibrosis.
Figure 1. Prenatally androgen exposed males exhibit characteristics typical of pre- and post-pubertal sons of 
PCOS women. (a) Plasma characterisation: Samples from control (C; n = 14) and prenatal androgen excess (PA; 
n = 14) were collected at 6 months postnatal age from male offspring and assessed for common characteristics 
of pre- and pubertal sons of PCOS women. Prenatally androgen treated male offspring had significantly elevated 
circulating AMH, insulin and triglycerides, with no alteration in terms of testosterone concentrations. (b) 
Plasma cholesterol profiles: Prenatally androgen treated male offspring had significantly elevated total, LDL and 
HDL cholesterol concentrations as compared to vehicle control animals. Differences were analysed by unpaired, 
two-tailed t-test. (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Box plot whiskers are lowest and 
highest observed values, box is the upper and lower quartile, with median represented by line in box.
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Systemic effects. Bioinformatic analysis of the profile of altered plasma proteins in postnatal, adolescent, 
prenatally androgen treated males was consistent with an increased risk of overall increased morbidity and mor-
tality. Altered pathways included diabetes mellitus, diabetic complications, occlusion of artery and atherosclerosis 
(Table 1). Indeed, postnatal, adolescent, prenatally androgen treated males had increased levels of fasting plasma 
insulin (0.55 ± 0.27 ng/ml vs 0.37 ± 0.10 ng/ml; P < 0.05) (Fig. 1A), consistent with a prenatally programmed 
reduction in health-span in adult males.
Hepatic expression of selected genes in fetal life. Hepatic expression of selected genes (altered in 
postnatal life by prenatal androgen excess) was investigated in fetal males, on day 90 of pregnancy, exposed 
to increased levels of androgens and compared to fetal controls. There was no difference in the expression of 
HMGCS1, HMGCR, NR1H4, RXRG, GSS, GSTM1, GSTO1, GPX4, GPX7, XDH however expression of CYP7A1 
and ABCC2 was significantly decreased in prenatally androgenised males (P < 0.05; Fig. 5).
Pathway P-Value Direction Molecules
Lipid metabolism
Metabolism of cholesterol 9.1 × 10−14 ↓ 31 genes
Sterol synthesis 1.08 × 10−13 ↓ 28 genes
Cholesterol synthesis 2.5 × 10−11 ↓ 23 genes
Lipid homeostasis 6.24 × 10−7 NP 29 genes
Disorder of lipid metabolism 4.46 × 10−5 ↑↑ 17 proteins
Homeostasis of lipid 1.23 × 10−5 NP 14 proteins
Metabolism of cholesterol 2.37 × 10−7 NP 12 proteins
Synthesis of cholesterol 1.8 × 10−4 NP 7 proteins
Cholesterol concentration 6.7 × 10−4 ↑ 16 proteins
Lipid homeostasis 7.85 × 10−5 NP 7 p proteins
Reverse cholesterol transport 7.64 × 10−5 NP 3 p proteins
Efflux of cholesterol 4.62 × 10−5 ↑ 6 p proteins
Hypercholesterolemia 7.34 × 10−4 NP 4 p proteins
Dysregulation of enterohepatic circulation and cholestasis
Altered bile acid synthesis 3 × 10−3 NP 4 proteins
Intrahepatic cholestasis 2 × 10−2 NP 8 genes
Cholestasis 1.5 × 10−3 NP 7 proteins
Reduced hepatic detoxification potential
Oxidative stress 1.23 × 10−6 ↑ 7 proteins
Hydrogen peroxide metabolism 5.93 × 10−3 ↓ 8 proteins
Synthesis of reactive oxygen species 1.4 × 10−3 ↑ 24 proteins
Concentration of glutathione 3.3 × 10−3 ↓ 7 proteins
Biosynthesis of hydrogen peroxide 6.37 × 10−4 ↑ 5 p proteins
Metabolism of reactive oxygen species 1.62 × 10−5 ↑ 14 p proteins
Synthesis of reactive oxygen species 2.18 × 10−4 ↑ 12 p proteins
Liver damage
Liver damage 6 × 10−4 ↑ 32 genes
Drug-induced liver disease 1.23 × 10−6 NP 9 genes
Hepatocyte proliferation 1.83 × 10−4 ↑ 20 genes
Increased cell death 2.37 × 10−7 ↑ 119 proteins
Fibrosis 5.9 × 10−4 ↑ 11 p proteins
Liver lesion 3.26 × 10−6 ↑ 54 p proteins
Hepatic injury 4.08 × 10−4 NP 7 p proteins
Liver cirrhosis 5.28 × 10−4 NP 7 p proteins
Systemic effects
Morbidity and mortality 1.49 × 10−9 ↑ 236 genes
Diabetes mellitus 1.88 × 10−7 NP 23 p proteins
Diabetic complications 6.33 × 10−5 NP 8 p proteins
Occlusion of artery 1.45 × 10−7 ↑↑ 16 p proteins
Atherosclerosis 2.01 × 10−7 ↑↑ 15 p proteins
Table 1. Bioinformatic characterisation of prenatally androgen exposed males. Dysregulated hepatic metabolic 
pathways and disease states associated with differentially expressed genes and proteins in adolescent prenatally 
androgenized males (p-protein = plasma protein) were highlighted. ↑/↓ = mild directionality prediction (Z 
score ≤ 2/−2); ↑↑/↓↓ = strong directionality prediction (Z score > 2/−2); NP = no prediction made.
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plasma markers of altered liver function during adolescence. We examined the plasma proteome 
to determine potential readouts of this pattern of dyslipidaemia associated with reduced hepatic cholesterol syn-
thesis and cholestasis. The plasma proteome highlighted intra-hepatic changes associated with cholesterol home-
ostasis, detoxification potential, hepatic damage and fibrosis (Table 4). Based upon the observation of reduced 
expression of CYP7A1 and ABCC2 in both fetal and postnatal livers from prenatal androgen excess pregnancies 
(Figs. 5,2 and 3 respectively), we performed correlation analyses between these two permanently differentially 
expressed genes, circulating cholesterol, and plasma biomarkers of cholesterol homeostasis, ROS detoxification 
and liver damage/fibrosis (Table 4). Based upon strength of correlation, whilst all plasma protein markers showed 
strong correlation with circulating cholesterol, the panel of fibrotic proteins, COL1A1, COL1A2, COL2A1 and 
COL5A1 were the most consistent in terms of robust fold changes in the circulation and association with reduced 
expression of CYP7A1 and ABCC2 genes in the liver (Table 4). This indicated potential utility of circulating mon-
omeric collagen peptides as markers of developing hepatic dysfunction.
Discussion
Suboptimal intrauterine environments can ‘programme’ adverse postnatal health outcomes. First degree male 
relatives of hyperandrogenaemic PCOS patients exhibit dyslipidaemia and hyperinsulinaemia26–28,32. We inves-
tigated whether excess developmental androgen exposure could explain postnatal male dyslipidaemia using an 
outbred clinically-realistic large-animal model, previously shown to parallel female offspring (fetal androgen 
excess models and human PCOS daughters) pancreatic function outcomes23–25,33. Adolescent prenatally androg-
enised ovine males had increased circulating concentrations of total cholesterol, HDL-C, LDL-C, TG, AMH and 
insulin, independent of body weight, adiposity and contemporary testosterone concentrations, thus faithfully 
reproducing the dyslipidaemic / endocrine profile of first degree male relatives of PCOS patients26–30. Neither 
these observations, nor those discussed below, were recreated by in utero estrogenic excess, underscoring the 
androgen-specific nature of the alterations reported (see Supplementary data set, Fig. 3), and decreasing the like-
lihood of metabolism of androgen to estrogen as a component mechanism driving observed effects.
Hypercholesterolemia in prenatally androgen treated males contrasted with downregulated cholesterol bio-
synthesis pathway genes (HMGCS1, HMGCR, MVD, FDPS, SQLE, CYP51A1, HSD17B7, NSDHL and DHCR7). 
Such endogenously suppressed de novo cholesterol synthesis, as a negative feedback response to increased circu-
lating cholesterol34, provides biologically consistent insight into why statin treatment is less effective35,36 in some 
individuals regarding cholesterol normalisation.
Since we did not find evidence of increased cholesterol synthesis, we focused on cholesterol absorption and 
excretion. Experimental control and prenatally androgen treated animals were fed a standard diet, with no evi-
dence of increased calorific intake in prenatally androgen treated males, either in terms of feeding behaviour 
or body weight/adiposity. Adolescent prenatally androgen-treated males had increased expression of hepatic 
Figure 2. Prenatally androgen exposed male offspring develop hepatic dysregulation of cholesterol and bile 
acid synthesis. Differentially expressed hepatic genes and proteins between control (C; n = 14) and prenatal 
androgen excess (PA; n = 14) adolescent offspring relevant to hepatic cholesterol homeostasis. To increase 
confidence in findings from RNAseq analysis a limited subset of genes was examined by qRT-PCR. In all cases 
differential expression was similar between RNAseq and qRT-PCR results. Fold change is PA compared to 
control animals. P values cited are nominal values, false discovery rate adjusted P values (FDR) were calculated 
as described by Benjamini and Hochberg (1995). Red denotes decreased, green denotes increased in response to 
prenatal androgen excess.
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chylomicron remnant receptors LRP1 and LRP5, suggestive of increased hepatic uptake of diet-derived cho-
lesteryl esters37–39. However, perhaps as a response to increased cholesterol uptake, these prenatally androgen 
treated animals also had increased expression of ABCG5 and ABCG8 that positively correlated with cholesterol 
concentrations (r = 0.53; P = 0.002). ABCG5 and ABCG8 are the heterodimer transporter pair that determine 
clearance of free cholesterol into bile40,41. Furthermore, increased biliary secretion of cholesterol underpins pre-
disposition to gallstone formation42–44, in turn increasing risk of extrahepatic cholestasis45.
Adolescent prenatally androgen treated males also displayed increased concentrations of plasma apolipo-
proteins, notably APOA4, APOC3, APOD and APOM, in agreement with their dyslipidaemic profile, and in 
turn strongly correlated with circulating cholesterol. APOA4, a component of HDL and chylomicrons, was also 
over-represented in liver. APOA4, primarily synthesised in small intestine with only minor amounts derived from 
liver, reflects dietary lipid absorption46,47, and is increased with progression of NAFLD severity48. Clearly, elevated 
plasma APOA4 likely indicates increased small intestinal lipid absorption in prenatally androgen treated animals, 
supported by a positive relationship between circulating cholesterol and plasma APOA4, increased ABCG5/8, 
and absence of relationship between plasma APOA4 protein and hepatic APOA4 mRNA (r 0.19, P > 0.05) or 
protein (r 0.27, P > 0.05). Increased intestinal cholesterol absorption, in combination with decreased cholesterol 
synthesis, is strongly associated with elevated cardiovascular risk49,50. This, in tandem with bioinformatic analy-
sis of plasma protein profiles defining atherosclerosis as a disease risk, reinforces the premise of prenatal excess 
androgen exposure as a factor in male lifelong health.
Whilst we observed no alterations in circulating bile acid concentrations, our prenatally androgen treated 
males had decreased hepatic CYP7A1 expression. CYP7A1 encodes the rate-limiting enzyme in the classic path-
way of cholesterol metabolism to bile acids51 (responsible for 90% of bile acid synthesis in humans52). Altered 
CYP7A1 expression negatively correlated with total cholesterol (r−0.9, P = 0.004), underscoring the likelihood 
of decreased metabolism of cholesterol into bile acids, thus offering opportunity for increased secretion / absorp-
tion, as witnessed by hepatic ABCG5/8 profiles and plasma APOA4 increase respectively. Pertinently, CYP7A1 
gene knockout mice have increased total- and LDL-cholesterol53, and the human CYP7A1 homozygous deletion 
Gene ID Template
Detection 
technique Fold change P value FDR
Liver detoxification potential
GSS mRNA RNAseq −1.2 0.002081 0.035
GSS mRNA qRT-PCR −1.3 0.005800 NA
GSR mRNA RNAseq −1.4 0.000131 0.008
GSTM1 mRNA RNAseq −1.5 0.004742 0.056
GSTM1 mRNA qRT-PCR −1.3 0.003400 NA
GSTM1 protein Proteomics −1.5 0.001069 0.100
GSTM4 protein Proteomics −2.8 0.001206 0.100
GSTO1 mRNA RNAseq −1.3 0.000523 0.016
GSTO1 mRNA qRT-PCR −1.2 0.015600 NA
GSTO1 protein Proteomics −1.2 0.013851 0.213
UGDH mRNA RNAseq −1.3 0.001314 0.027
UGDH protein Proteomics −1.2 0.025751 0.274
UGT2B7 protein Proteomics −1.3 0.012154 0.200
UGT3A2 mRNA RNAseq 1.2 0.004124 0.052
ROS detoxification
GPX4 mRNA RNAseq −1.3 0.000187 0.009
GPX4 protein Proteomics −1.3 0.022405 0.252
GPX7 mRNA RNAseq 1.7 0.000000006 0.00002
GPX7 mRNA qRT-PCR 1.5 0.000700 NA
PRDX5 mRNA RNAseq −1.2 0.001224 0.026
PRDX5 protein Proteomics −1.2 0.014872 0.221
TXN mRNA RNAseq −1.2 0.002934 0.043
TXN protein Proteomics −1.2 0.062923 0.375
Table 2. Differentially expressed hepatic genes and proteins relevant to liver detoxification between control and 
prenatal-androgen excess pregnancies in male adolescent offspring. Differentially expressed hepatic genes and 
proteins between control (C; n = 14) and prenatal androgen excess (PA; n = 14) adolescent offspring relevant 
to liver detoxification. False discovery rate (FDR) was determined by Benjamini and Hochberg (1995) method. 
Data are fold change in PA animals relative to vehicle treated animals. To increase confidence in findings from 
RNAseq analysis a limited subset of genes was examined by qRT-PCR. In all cases differential expression was 
similar between RNAseq and qRT-PCR results. In a small number of selected cases, where a protein has either 
particular relevance as part of a subset of proteins with related function, or where its gene was found to be 
differentially regulated, we have reported fold changes of those which were not statistically significant after FDR 
control (nominal and adjusted P values cited in all such cases).
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mutation is associated with hypercholesterolemia, HMG-CoA reductase inhibitor resistance and premature cor-
onary disease54. Conversely, CYP7A1 overexpression is characterized by elevated bile acid pool, increased hepatic 
cholesterol synthesis and lowered serum cholesterol55,56. Resveratrol can induce CYP7A1 expression, increase 
bile acid pool, reduce hypercholesterolemia57 and attenuate liver injury / cholestasis58,59, suggesting a potential 
intervention for prenatally programmed hepatic dysfunction.
Efficient bile acid synthesis is critical for cholesterol homeostasis. Both dyslipidaemia and cholestasis, here 
predicted by IPA bioinformatics and evidenced by hepatic and circulatory endpoints, may have fetal origins60. 
CYP7A1 epigenetic modulation during development is an offspring outcome of maternal protein restriction61,62, 
while intra-uterine calorie restriction causes decreased CYP7A1 expression during fetal and postnatal life, result-
ing in male-specific hypercholesterolemia61,62. We noted that CYP7A1 was also significantly depressed in fetal 
livers from prenatally androgen treated males compared to gestational age matched controls. No changes in fetal 
expression of de novo cholesterol synthesis genes were observed, suggesting decreased cholesterol synthesis in 
adolescents may be consequential of the novel concept of decreased CYP7A1 expression ‘programmed’ by andro-
gen excess in utero.
Adolescent prenatally androgen treated males had increased hepatic expression of NR1I2 (PXR) and VDR, but 
decreased NR1H4 (FXR). This in turn may be reflective of altered bile acid signaling63–66, due to differential recep-
tor regulation by primary and secondary bile acids63,65,67 (partially dependent upon bile acid hydrophobicity68–70). 
Figure 3. Prenatally androgen exposed develop hepatic dysregulation of cholesterol and bile trafficking.: 
Enterohepatic circulation. Differentially expressed hepatic genes and proteins between control (C; n = 14) 
and prenatal androgen excess (PA; n = 14) adolescent offspring relevant to hepatic regulation of cholesterol, 
bilirubin, bile acids and organic substrates trafficking. False discovery rate (RNAseq and proteomics; FDR) 
was determined by Benjamini and Hochberg (1995) method. Data are fold change in PA animals relative to 
vehicle treated animals. To increase confidence in findings from RNAseq analysis a limited subset of genes was 
examined by qRT-PCR. In all cases differential expression was similar between RNAseq and qRT-PCR results. 
In a small number of selected cases, where a protein has either particular relevance as part of a subset of proteins 
with related function, or where its gene was found to be differentially regulated, we have reported fold changes 
of those which were not statistically significant after FDR control (nominal and adjusted P values cited in all 
such cases).
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Hepatocyte retention of hydrophobic bile acids is causative of liver damage in cholestasis68. Furthermore, the role 
of FXR in bile acid homeostasis, liver regeneration71, and cholestatic disease72,73 has received significant attention, 
not least in terms of being a therapeutic target74–76. Therefore, this finding of reduced FXR expression is particu-
larly interesting.
ABCC2 mRNA, encoding MRP2, which mediates canalicular excretion and detoxification of a broad range 
of compounds, including bilirubin and xenobiotics77, was decreased in the livers of our adolescent prenatally 
androgen treated males. An absence of functional MRP2 from the canalicular membrane is associated with con-
jugated hyperbilirubinemia and ‘dark pigment’ deposition in hepatocytes in the hereditary ABCC2 deficiency 
Dubin-Johnson syndrome (DJS)78,79, Eisai hyperbilirubinemic rats80,81 and knockout mouse strains82. These 
are in close concordance with our observations of increased plasma bilirubin concentration and hepatic accu-
mulation in our prenatally androgen treated males. Decreased ABCC2 may be functionally compensated for 
by upregulation of ABCC3 (MRP3) and ABCC4 (MRP4) in DJS patients and animal models of cholestasis82–85. 
Figure 4. Prenatally androgen exposed male offspring develop increased hepatic bilirubin accumulation, 
increased circulatory bilirubin concentrations, and increased circulating ALP, without any significant alterations 
circulating bile acid concentration. Plasma samples collected at 6 months postnatal age from male offspring 
were assayed for bilirubin, bile acids and ALP; incidence of bilirubin accumulation in liver was determined 
histologically after oxidisation to biliverdin via Fouchet’s reagent (indicated by black/green punctate staining, 
upper panels). Increased circulating total bilirubin, hepatic bilirubin accumulation incidence and plasma ALP 
were noted in PA males. Representative images of sections from each prenatal treatment group are shown (x20 
magnification). Differences were analysed by unpaired, two-tailed t-test in plasma, and Chi-square in the case of 
incidence of hepatic bilirubin accumulation (*P < 0.05; **P < 0.01, ***P < 0.001). Box plot whiskers are lowest 
and highest observed values, box is the upper and lower quartile, with median represented by line in box.
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However, prenatally androgen treated males showed no compensatory increase in ABCC3, while ABCC4 expres-
sion was downregulated. Our data indicated an extremely strong correlation between depressed ABCC2 and 
NR1H4 mRNA (encoding FXR) expression (r 0.91, P < 0.0001). This is in keeping with FXR’s regulatory role over 
ABCC286,87. Adolescent prenatally androgenised males also had decreased expression of RDX mRNA (encod-
ing radixin), which is required for MRP2 anchoring in the canalicular membrane88,89. RDX-deficient mice show 
increasing serum bilirubin concentrations, culminating in mild liver injury by 8 weeks postnatal age90. Although 
attenuated MRP2 is not of itself a major cause of cholestasis, it is decreased in patients with cholestasis91–93, in 
turn leading to clinical presentations including fibrosis, cirrhosis, liver failure or hepatobiliary malignancy94. In 
addition, our prenatally androgen treated male offspring also displayed increased plasma ALP, in the absence 
of increased ALT, a common characteristic of cholestasis95,96. We conclude, therefore, that an outcome of fetal 
androgen excess is increased male cholestatic disease risk.
Adolescent prenatally androgen treated males had decreased hepatic expression of GSH synthetase (GSS), 
glutathione reductase (GSR), (implying altered oxidative stress response97); and glutathione S-transferase genes 
(GSTM1, GSTM4 and GSTO1) (involved in conjugation prior to transport via MRP efflux pumps98). Decreased 
GSH levels are associated with disease states99. Such reduced detoxification potential in prenatally androgen 
treated males was accompanied by increased PXR expression. PXR activates phase I drug metabolizing P450 
enzymes, phase II drug conjugation enzymes, and phase III drug transporters, including MRP2100–102. However, 
as discussed above, in our study, ABCC2 and phase II enzyme expression were decreased. PXR (and FXR) 
form heterodimers with retinoid X receptors RXRA, RXRB and RXRG103. Our adolescent prenatally androgen 
treated males had markedly decreased hepatic RXRG expression, which in turn may have impacted detoxifica-
tion enzyme transcript expression. It is noteworthy that several studies in humans and animal models report 
decreased glutathione in cholestasis104–107. In agreement with our results, expression of proteins UGT2B7 (pro-
tein), GSTM1 (mRNA and protein) and GSTM4 (protein) are reduced in obstructive cholestasis105, and we extend 
this panel to include GST01 (mRNA and protein). A similar expression profile of nuclear receptors to that which 
we observe, with increased PXR, VDR, PPARA and decreased FXR expression105, and downregulation of CYP7A1 
expression, was also reported in human obstructive cholestasis108. Prenatally androgen treated males also had 
decreased hepatic glutathione peroxidase 4 (GPX4), peroxiredoxin 5 (PRDX5) and thioredoxin (TXN), anti-
oxidant enzymes that protect cells against oxidative damage109–111. In terms of consequential changes linked to 
altered transcripts/proteins, increased expression of glutathione peroxidase 7 (GPX7), an oxidative stress sen-
sor112, in our prenatally androgen treated males, in combination with decreased plasma catalase (CAT), glu-
tathione peroxidase 3 (GPX3) and superoxide dismutase 3 (SOD3), yields an antioxidant enzyme profile strongly 
consistent with chronic liver diseases113.
Gene ID Template
Detection 
technique Fold change P value FDR
Fibrosis regulation and signalling
FGF7 mRNA RNAseq 1.5 0.000136 0.008
FGFR2 mRNA RNAseq 1.2 0.000974 0.023
FGFR3 mRNA RNAseq 1.3 0.000001 <0.001
FGFRL1 mRNA RNAseq 1.3 0.000034 0.003
SMAD3 mRNA RNAseq 1.3 0.002605 0.040
SMAD7 mRNA RNAseq 1.4 0.000252 0.011
TGFA mRNA RNAseq 1.2 0.000107 0.007
TGFBI mRNA RNAseq 1.2 0.003776 0.049
Fibrosis effectors
COL1A1 protein Proteomics 2.2 0.046590 0.330
COL4A1 mRNA RNAseq 1.3 0.000892 0.022
COL4A2 mRNA RNAseq 1.2 0.007580 0.074
COL4A4 mRNA RNAseq 1.3 0.013936 0.103
COL4A5 mRNA RNAseq 1.8 0.000008 0.001
COL4A6 mRNA RNAseq 10.3 <0.000001 <0.001
COL6A6 mRNA RNAseq 1.3 0.013089 0.099
COL18A1 mRNA RNAseq 1.4 0.000015 0.002
COL27A1 mRNA RNAseq 1.4 0.002068 0.035
Table 3. Differentially expressed hepatic genes and proteins relevant to liver fibrosis between control and 
prenatal-androgen excess pregnancies in male adolescent offspring. Differentially expressed hepatic genes and 
proteins between control (C; n = 14) and prenatal androgen excess (PA; n = 14) adolescent offspring relevant to 
liver fibrosis markers. False discovery rate (FDR) was determined by Benjamini and Hochberg (1995) method. 
Data are fold change in PA animals relative to vehicle treated animals. In a small number of selected cases, 
where a protein has either particular relevance as part of a subset of proteins with related function, or where its 
gene was found to be differentially regulated, we have reported fold changes of those which were not statistically 
significant after FDR control (nominal and adjusted P values cited in all such cases).
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In order to comprehend early life underpinnings of decreased hepatic detoxifying potential, we assessed 
expression of ABCC2 and selected detoxifying enzymes in livers from control and prenatally androgen treated 
fetuses. Interestingly, only ABCC2 was downregulated in fetal life by androgen excess, indicative that decreased 
detoxification potential may be secondary to reduced ABCC2 expression.
Male cholestasis due to anabolic androgenic steroid abuse114 is mechanistically associated with increased oxi-
dative stress115 and deficiency in hepatic canalicular transporters116. Whether this phenomenon is male specific 
in humans is unknown, but in male rodents, raised testosterone can decrease MRP2 mRNA and protein, with 
no effect observed in females117. We suggest individualised approaches to treatment, accounting for the stage 
of cholestatic disease development118 may also benefit from understanding of early life contributions to disease 
development and/or susceptibility.
Early stage markers of different liver diseases, ideally with prognostic value, are acutely required118. The utility 
of new molecular techniques for biomarker discovery is demonstrated by shotgun plasma proteomic assess-
ment of NAFLD48. Furthermore, the most robust patho-biochemical signatures identified in a murine model of 
obstructive cholestasis include increased bilirubin and COL1A1119,120, which we also note elevated in circulation 
here. We observed increased hepatic expression of collagen genes, and increased collagen proteins in plasma 
of prenatally androgen treated males. We also noted elevated expression of hepatic transforming growth factor 
beta induced protein (TGFBI) (also increased in NAFLD plasma)48, SMAD-3 and -7, FGF7 (which correlates 
with hepatic fibrosis severity121,122 and suppresses CYP7A1 during fibrosis development123), FGFR2 and FGFR3. 
Collectively, this indicated a pro-tissue remodelling/pro-fibrotic hepatic environment developing. In light of 
collagen-1 as a potential prognostic marker of fibrosis in biliary atresia124, we suggest that in combination with 
circulating cholesterol and bilirubin, COL1A1, COL1A2, COL2A1 and COL5A1 may constitute circulating 
markers of early stage, pre-symptomatic cholestatic disease development in at risk individuals.
Figure 5. Examination of differentially expressed genes identified in adult life as consequential of prenatal 
androgen excess by qPCR in fetal livers (day 90 of gestation) during androgen excess treatment. Control (C; 
n = 10) and prenatal androgen excess (PA; n = 6) male fetal livers were examined by qPCR in terms of genes 
identified as differentially expressed during adolescence attributable to prenatal androgen status. Statistical 
testing by unpaired, two tailed Student t test, (*P < 0.05). Of all genes examined, only CYP7A1 and ABCC2 
mRNA were depressed in fetal life (in addition to postnatal life) by fetal androgen excess. Box plot whiskers are 
lowest and highest observed values, box is the upper and lower quartile, with median represented by line in box.
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We recognise three major limitations to this work. Only a single postnatal time point was studied; however, 
we see no suggestions here that the condition we describe was likely to spontaneously resolve in later life. We 
acknowledge species difference between humans and sheep, and that a single dose of testosterone was used, none-
theless, our data closely parallels human clinical outcomes (dyslipidaemia and hormonal alterations) of hyper-
androgenaemic pregnancy conditions, and mechanistic investigations performed in laboratory rodent models of 
hepatic disease
In conclusion, the legacy of male fetal androgenic excess is the development of a cholestasis-like condition in 
adolescence, accompanied by dyslipidaemia and increased fibrotic potential. We report fetal androgen excess as 
a risk factor for poor male hepatic/metabolic health.
Materials and Methods
Statistical analysis. All experiments were carried out on n = 14 male offspring per group, except in the 
case of a limited estrogenic overexposure comparison (see Supplementary Materials), and in the case of fetal 
tissue analyses (actual numbers described in methods and results sections). No animals or data were excluded 
from any of the analyses described. RNAseq and proteomic data was examined by pairwise comparisons, using 
Benjamini and Hochberg (1995) false discovery rate control. In cases of single gene analyses, all data sets were 
normality tested prior to further analysis (Shapiro-Wilk test), and logarithmically transformed if necessary. For 
comparing means of two treatment groups with equal variances, unpaired, two-tailed Student’s t test was used 
accepting P < 0.05 as significant. Bonferroni multiple test correction was utilised in the case of data subjected 
to t-test. A Chi-square test was used for testing categorical variables. Correlation was assessed by calculation of 
Pearson product-moment co-efficient. Statistical analysis software package R (version 3.4.0) was utilised for all 
RNAseq and proteomic analyses, and the remainder of statistical analysis was performed using GraphPad Prism 
8.0 software (GraphPad Prism Software, San Diego, CA, USA). All P values are cited in full.
Study approval. All studies were approved by the UK Home Office and conducted under approved Project 
Licence PPL 60/4401, reviewed by The University of Edinburgh Animal Research Ethics Committee.
Animals and tissue collection. All animal based components of the study were conducted under natu-
ral lighting conditions with no environmental manipulations. Animal husbandry, experimental protocols and 
tissue collection were performed as are exactly as previously described23,24. Briefly, mature Scottish Greyface 
ewes were fed in order to achieve a comparable body condition score (2.75–3) prior to estrous cycle synchroni-
sation. After a synchronised mating (Texel ram), animals were allocated at random to one of two experimental 
Plasma protein PA fold change FDR Plasma Cholesterol Hepatic CYP7A1 mRNA Hepatic ABCC2 mRNA
Cholesterol homeostasis
APOA1 1.4 0.344 r 0.53 P 0.0055 r −0.30 NS r −0.19 NS
APOA2 1.3 0.137 r 0.71 P < 0.0001 r −0.32 NS r −0.35 NS
APOA4 1.7 0.014 r 0.49 P 0.0044 r −0.23 NS r −0.41 P = 0.018
APOC3 2.0 0.037 r 0.74 P < 0.0001 r −0.16 NS r −0.28 NS
APOD 1.8 0.001 r 0.77 P < 0.0001 r −0.32 NS r −0.44 P = 0.012
APOM 1.5 0.034 r 0.71 P < 0.0001 r −0.39 P = 0.021 r −0.49 P = 0.006
ROS detoxification potential
CAT −2.8 0.052 r −0.47 P = 0.0171 r 0.55 P = 0.0055 r 0.49 P = 0.014
GPX3 −1.7 0.043 r −0.39 P = 0.022 r 0.39 P = 0.025 r 0.46 P = 0.009
SOD3 −2.0 0.018 r −0.42 P = 0.015 r 0.24 NS r 0.44 P = 0.011
Damage/fibrosis
COL1A1 2.3 0.044 r 0.55 P = 0.0016 r −0.34 P = 0.046 r −0.62 P = 0.0004
COL1A2 6.1 0.001 r 0.67 P = 0.0001 r −0.45 P = 0.011 r −0.59 P = 0.0009
COL2A1 1.9 0.279 r 0.36 P = 0.043 r −0.55 P = 0.0034 r −0.45 P = 0.015
COL5A1 2.2 0.037 r 0.59 P = 0.0021 r −0.59 P = 0.0025 r −0.67 P = 0.0004
Table 4. Differentially expressed plasma proteins relevant to cholesterol homeostasis, ROS detoxification 
potential and liver damage and fibrosis, and their relationships to gene expression altered in both fetal and 
postnatal life. Differentially expressed plasma proteins between control (C; n = 14) and prenatal androgen 
excess males (PA; n = 14) during adolescence, with relevance as markers of hepatic cholesterol homeostasis, 
detoxification and fibrotic response were identified. Fold changes are those in PA animals relative to vehicle 
treated animals. False discovery rate (FDR) was determined by Benjamini and Hochberg (1995) method. In the 
case of APOA1 we have reported fold change which was not statistically significant after FDR control (nominal 
and adjusted P values cited), since this forms part of a family of apolipoproteins which were significantly 
altered by prenatal treatment in postnatal adolescent male offspring. Correlation was assessed by calculation 
of the Pearson r product-moment co-efficient, with P < 0.016 accepted as significant (Bonferroni multiple 
comparisons adjusted). Collagen proteins, in terms of both fold change in plasma and correlation with CYP7A1, 
ABCC2 and circulating total cholesterol were the most robust markers of prenatal androgen excess hepatic 
dysfunction/dyslipidaemia.
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groups – vehicle control or testosterone propionate (TP) exposed. Treatment occurred on day 62 and day 82 of 
gestation (post-sexual differentiation, designed to maintain elevated testosterone concentrations over experi-
mental period23,24). Anaesthesia was induced on day 62 of gestation by initial sedation via administration of 10 mg 
Xylazine i.m (‘Rompun’, Baylor plc Animal Health Division, UK), followed by 2 mg/kg ketamine (i.v, Keteset, 
Fort Dodge Animal Health, UK). All downstream procedures were conducted under surgical aseptic conditions. 
TP was dissolved in vegetable oil (100 mg/ml) and a 200 μl volume injected (20 G Quinke spinal needle, BD 
Biosciences) via ultrasound guidance into the fetal flank (intraperitoneal injection). Control fetuses received 
200 μl vegetable oil vehicle alone. In order to account for potential aromatisation of testosterone to estrogen, and 
thus incorrect interpretation of effects being attributable to androgenic excess, an additional treatment group 
of estrogenic overexposure (n = 8) was created by exposing fetuses, in an identical manner to androgen excess 
exposure, by injection of 200 µl of 20 mg/ml DES (diethylstilbesterol), this lower dose as compared to testosterone 
being selected on the basis of binding affinity of DES as compared to the naturally occurring estradiol receptor 
ligand estradiol-17β125. These procedures were repeated on d82 of gestation. Immediately after surgical procedure 
completion all pregnant ewes were given prophylactic antibiotics (Streptacare, Animalcare Ltd, UK, 1 ml/25 kg) 
and were then monitored during recovery; no adverse effects of these procedures were observed.
Fetal tissue collection was as previously described, performed on day 90 of gestation (day 147 is term)23,24.
Offspring were lambed and reared conventionally (weaned at 3 months postnatal age). At birth, and during 
postnatal life, we saw no phenotypic evidence of any deleterious effects of the treatment regimens used. In female 
children of PCOS sufferers, early puberty (Tanner 1 developmental stage) is when measurable metabolic pertur-
bations (hyperinsulinaemia) begin to manifest, hence the 6 months postnatal age studied here, as an equivalent 
of the human observations126. Prior to sacrifice at 6 months of age, all animals received a bolus injection of glu-
cose (10 g glucose in 20 ml saline), and 15 minutes post injection sacrifice was achieved via barbiturate overdose. 
Animals were sacrificed in a random order with respect to treatments. Tissues were recovered immediately, and 
snap frozen prior to storage at −80 °C until downstream analysis.
In both fetal and postnatal tissue collection, liver sampling occurred from the same lobe (right posterior), 
in approximately the same area, and was immediately snap frozen, then stored at −80 °C until further process-
ing in the case of nucleic acid and protein extraction, or fixed and processed as previously described23,24. These 
procedures were repeated over two breeding seasons, maintaining all conditions identically, to ensure sufficient 
numbers of male offspring for analysis.
RnA and protein extraction. RNA and protein were extracted and purified using Qiagen AllPrep kits, fol-
lowing manufacturer’s instructions. All samples were randomised within a larger study set to control for potential 
batch effects. RNA concentrations were determined using a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific, UK), with Agilent Bioanalyser analysis utilised for RNA quality control – all samples processed for 
downstream analysis recorded a RIN value of >7.5. RNA and protein extracts were stored at −80 °C until further 
analysis.
RNA sequencing transcriptomic analyses. 1 μl of ERCC (External RNA Controls Consortium) spike in 
controls were added to 500 ng of RNA sample to permit library quality assessment and estimation of lowest limit 
of detection127. One of the two ERCC mixes were selected at random for each sample. Libraries were prepared 
with the Illumina TruSeq Stranded mRNA kit, using fetal-vehicle treated (control) liver samples (n = 14) and 
fetal-testosterone propionate treated liver samples (n = 14), sampled at 6 months postnatal age. Sequencing was 
performed on the NextSeq. 500 High Output v2 kit (75 cycles) on the Illumina NextSeq. 500 platform producing 
75 bp single end reads. Raw sequencing data is available from the ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-8032. To assess quality of sequencing data, reads were ana-
lysed with FastQC (version 0.11.3)128. To remove any lower quality and adapter sequences, TrimGalore! (version 
0.4.0)129 was used to filter the reads (phred quality score threshold of 30). To remove the ERCC reads, all reads 
were aligned to the ERCC reference genome using HISAT2 (version 2.1.0)130. These alignments were processed 
using SAMtools (version 1.2)131, reads were counted using featureCounts (part of the sub read version 5.0.1 pack-
age)132 and analysed using the R package erccdashboard (version 1.6.0)133.
The most recent release of the sheep Ovis aries reference genome was downloaded from NCBI (https://www.
ncbi.nlm.nih.gov/genome?term = ovis%20aries)134 along with the equivalent annotation file, and reads were 
aligned to this reference using HISAT2 (version 2.1.0)130 with the parameter for stranded library preparation 
used. SAMtools (version 1.2)131 was used to process the alignments and reads were counted at gene locations 
using featureCounts (part of the sub read version 5.0.1 package)132 utilising the parameter to split multi-mapped 
reads as a fraction across all genes that they align to. Pairwise gene comparisons were carried out with edgeR 
(version 3.16.5)135 with all genes with CPM (count per million) value of more than one in six kept for analysis, 
and all other genes removed as low count genes, leaving 15134 genes for analysis. P values were adjusted using the 
Benjamini-Hochberg procedure, with a false discovery rate (FDR) set at q < 0.05136.
Liver and plasma protein quantification. Hepatic and plasma proteins were identified and quantified 
using a Q Exactive Plus hybrid quadrupole Orbitrap mass spectrometer fitted with an EASY-Spray nano-ESI 
source (Thermo Scientific) as previously described137. Briefly, 10 micrograms of proteins were diluted in 100 μl 
of 50 mM NH4HCO3 (BioUltra grade, Sigma Aldrich), and were reduced, alkylated and digested with trypsin 
overnight according to the PRIME-XS protocol (http://www.primexs.eu/protocols/Public-Documents/04%2
D%2D-Protocols/PRIME-XS-Protocol-NPC-In-Solution Digestion.pdf/). The equivalent of 2 μg of peptides 
(assuming no losses) were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). All 
peptide matching searches were performed against FASTA file of the ovine, bovine, swine, equine, and caprine 
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proteomes (canonical and isoform sequences retrieved from Uniprot on the 22nd of February 2018). Match 
between runs was used to identify peptide signals lacking MS/MS information. Protein intensities across sam-
ples were normalized using the maxLFQ algorithm138. Normalised protein intensities for all proteins were then 
extracted from the results file for the downstream statistical analyses. Pairwise protein comparisons were carried 
out using limma139 for those proteins that yielded normalised intensities in at least 75% of the compared samples. 
P values were adjusted using the Benjamini-Hochberg procedure136. Mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium via the PRIDE140 partner repository with the dataset iden-
tifier PXD014050.
Quantitative pcR. Quantitative PCR was performed exactly as previously described23, utilising Genorm 
analysis (PrimerDesign Ltd, UK) in order to identify a panel of two stable housekeeping genes – thus the geomet-
ric mean of ATPsynth and RPL19 was used as the normalisation reference. Negative controls consisted of an RT-ve 
and a template negative reaction. Primers were designed in house using the Primer3Plus bioinformatics software 
tool, were synthesised by Eurofins MWG Operon, Germany, and were validated prior to use (Supplementary 
Table 1), or were outsourced and designed by PrimerDesign Ltd, (UK).
Bioinformatic analysis. IPA (Ingenuity Pathway Analysis, Qiagen) was used to perform initial screens 
of affected pathways, and to identify potential disease states associated with the differentially expressed genes 
(DEG’s) and differentially expressed proteins (DEP’s). Pre-filtering of data uploaded to IPA was based upon FDR 
adjusted significance, using q < 0.05 as cut-off.
IPA P values of <0.05 (Right-tailed Fishers exact test) delivered information regarding association of signif-
icant DEG with biological processes, and directional change with regards to such biological pathways in health 
and disease generated where possible. Given smaller numbers of proteins identified, in order to generate mean-
ingful bioinformatics analyses, we relaxed the stringency of input by using nominal P values of <0.05.
plasma analyte determination. Concentrations of fasting plasma total cholesterol, high density lipo-
protein (HDL), Triglyceride (TG) total bilirubin, alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP) were obtained using commercial assay kits (Alpha Laboratories Ltd., Eastleigh, UK) as per manufacturer’s 
instruction, using a Cobas Mira automated analyser (Roche Diagnostics Ltd, UK). Low density lipoprotein (LDL) 
was calculated by the Friedewald equation141. For all assays within-run and intra-batch precisions were <4% CV 
and <5% CV, respectively. Fasting plasma bile acid concentration was measured using Total Bile Acid Assay Kit 
(STA-631; Cell Biolabs, INC., San Diego, US), as per the manufacturer’s instructions with all samples assayed in 
duplicate. The assay sensitivity was 0.39 µM and intra-assay CV was <4%. Plasma insulin was measured using 
the ALPCO Ovine Insulin Elisa kit (80-INSOV-E01; American Laboratory Products Company, Salem, US) as 
per the manufacturer’s instructions, with all samples measured in duplicate. The assay sensitivity was 0.15 ng/ml 
and intra-assay CV was <4.5%. Testosterone was measured by in-house ELISA. Briefly, 96-well plates (Greiner 
Bio-One GmbH, Germany) were coated with 100 µl of donkey anti rabbit IgG (Jackson ImmunoResearch Inc, 
USA) (1:500 in ELISA coating buffer, 100 mM Sodium Bicarbonate, pH 9.6) and incubated (4 °C, 12 hours). After 
washing twice (0.05 M Tris/HCl + 0.05% Tween 20, pH 7.4), 250 μl of Blocking buffer was added and incubated 
for 1 h (room temperature with shaking), then washed twice. Standards (0–24.3 ng/ml), samples and controls 
(20 µl per well) were added to each well, followed by 80 µl of Testosterone-HRP conjugate (Astra Biotech GmbH, 
Germany) at 1:20,000 in assay buffer (PBS pH 7.4, 0.1%BSA with 250 ng/ml cortisol (to displace any testosterone 
bound to binding globulins)), followed by 50 μl of Rabbit anti Testosterone −19 antibody (AMS Biotechnology, 
USA) (1:200,000). Plates were incubated (room temperature, 2 hours) then washed 5 times. 120 µl of substrate 
solution (3,3,5,5-Tetramethylbenzidine, Millipore Corporation, USA) was added and incubated (room tempera-
ture, in darkness, 20 min). Reaction was stopped by adding 80 µl of 2 N H2SO4 solution, and. plates read at 450 nm. 
The inter-assay CV for low and high testosterone QC pools were 11.4 and 9.1% respectively; intra-assay CV’s were 
8.9 and 5.6%, with detection limit of 0.1 ng/ml. Dihydrotestosterone cross-reacted 20.4%, all other tested steroids 
showed <0.2% cross-reactivity.
Hepatic bilirubin content. Wax embedded tissue sections (5 μm; 2 per sample), were mounted on to 
charged slides (Superfrost Plus, Thermoscientific, Epsom, UK), then rehydrated through a graded alcohol series. 
Halls Bilirubin stain was then performed, using Fouchets and Van Giesons reagents (Sigma Aldrich, Poole, 
Dorset) following an online protocol (https://webpath.med.utah.edu/HISTHTML/MANUALS/BILE.PDF). 
Assessment by light microscopy was performed by two independent operators, both blinded to treatment. 
Scoring was semiquantitive, categorical based, where 0 = no bilirubin deposits, 1 = mild and 2 = intense bilirubin 
deposits).
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